In the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) recruiting patients with myocardial infarction and high CRP levels of ≥2 mg/dl at baseline, it was revealed that only 55% of patients receiving 150-mg canakinumab achieved CRP levels of <2 mg/dl at 3 months, thereby resulting in significant cardiovascular risk reduction, rather than those with achieved CRP levels of ≥2 mg/dl [14]. This evidence concerns the gene CRP and myocardial infarction.